Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Biote (BTMD) over the last 4 years, with Q3 2025 value amounting to $24039.0.

  • Biote's Gains from Sales and Divestitures fell 9459.53% to $24039.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $24039.0, marking a year-over-year decrease of 9459.53%. This contributed to the annual value of $444783.0 for FY2024, which is 6443.19% down from last year.
  • According to the latest figures from Q3 2025, Biote's Gains from Sales and Divestitures is $24039.0, which was down 9459.53% from $24039.0 recorded in Q2 2025.
  • In the past 5 years, Biote's Gains from Sales and Divestitures registered a high of $2.1 million during Q4 2022, and its lowest value of $24039.0 during Q2 2025.
  • For the 4-year period, Biote's Gains from Sales and Divestitures averaged around $644385.0, with its median value being $444783.0 (2024).
  • As far as peak fluctuations go, Biote's Gains from Sales and Divestitures skyrocketed by 2568.43% in 2023, and later tumbled by 9459.53% in 2025.
  • Quarter analysis of 4 years shows Biote's Gains from Sales and Divestitures stood at $2.1 million in 2022, then plummeted by 39.11% to $1.3 million in 2023, then plummeted by 64.43% to $444783.0 in 2024, then crashed by 94.6% to $24039.0 in 2025.
  • Its last three reported values are $24039.0 in Q3 2025, $24039.0 for Q2 2025, and $444783.0 during Q4 2024.